https://bioxodes.com/ monthly 1.0 https://bioxodes.com/about-us monthly 1.0 https://bioxodes.com/product/biox-101 monthly 1.0 https://bioxodes.com/product/pipeline monthly 1.0 https://bioxodes.com/product/clinical-trial monthly 1.0 https://bioxodes.com/investors monthly 1.0 https://bioxodes.com/contact monthly 1.0 https://bioxodes.com/careers monthly 1.0 https://bioxodes.com/condition/forward-looking-statements monthly 1.0 https://bioxodes.com/condition/terms-conditions monthly 1.0 https://bioxodes.com/condition/privacy-cookie-policy monthly 1.0 https://bioxodes.com/condition/quality-policy monthly 1.0 https://bioxodes.com/condition/privacy-policy monthly 1.0 https://bioxodes.com/newsroom/events monthly 1.0 https://bioxodes.com/newsroom/publications monthly 1.0 https://bioxodes.com/newsroom/press-releases monthly 1.0 https://bioxodes.com/newsroom/media-articles monthly 1.0 https://bioxodes.com/newsroom/events/isth-2019 monthly 0.8 https://bioxodes.com/newsroom/publications/dual-inhibition-of-factor-xiia-and-factor-xia-as-a-therapeutic-approach-for-safe-thromboprotection monthly 0.8 https://bioxodes.com/newsroom/events/bio-europe-fall-2019 monthly 0.8 https://bioxodes.com/newsroom/events/isth-ssc-2018 monthly 0.8 https://bioxodes.com/newsroom/events/isth-2017 monthly 0.8 https://bioxodes.com/newsroom/events/isth-ssc-2016 monthly 0.8 https://bioxodes.com/newsroom/events/isth-2015 monthly 0.8 https://bioxodes.com/newsroom/publications/anticoagulation-with-an-inhibitor-of-factors-xia-and-xiia-during-cardiopulmonary-bypass monthly 0.8 https://bioxodes.com/newsroom/publications/ir-cpi-a-coagulation-contact-phase-inhibitor-from-the-tick-ixodes-ricinus-inhibits-thrombus-formation-without-impairing-hemostasis monthly 0.8 https://bioxodes.com/newsroom/publications/are-ticks-the-answer-to-medical-device-associated-clotting monthly 0.8 https://bioxodes.com/newsroom/publications/ir-cpi-an-original-inhibitor-of-thrombosis-and-thrombosis-associated-with-cancer monthly 0.8 https://bioxodes.com/newsroom/publications/efficacy-of-a-novel-contact-pathway-inhibitor-ir-cpi-in-an-extracorporeal-membrane-oxygenator-model monthly 0.8 https://bioxodes.com/newsroom/publications/evaluation-of-the-effects-of-a-novel-contact-pathway-inhibitor-ir-cpi-on-in-vitro-platelet-function-and-coagulation monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-appoints-dr-hans-warrinnier-as-chief-medical-officer monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-announces-the-completion-of-the-active-phase-of-its-first-in-human-study-performed-in-healthy-adult-volunteers-with-ir-cpi monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-obtains-authorization-to-launch-phase-i-trial-of-its-antithrombotic-drug-ir-cpi-in-healthy-male-volunteers monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-raises-eur-765-million-to-cover-its-clinical-phase-i-study-and-to-obtain-first-proofs-of-efficacy-in-patients monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-raises-eur-79-million-to-bring-ir-cpi-to-the-clinic monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-antithrombotic-meets-development-milestones-company-to-launch-series-a-financing-round-to-bring-product-to-the-clinic monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-raises-eur-26-million-to-develop-antithrombotic-peptide-derived-from-tick-saliva monthly 0.8 https://bioxodes.com/newsroom/events/healthtech-innovation-days-4 monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-appoints-marc-dechamps-as-new-ceo monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-to-present-at-biotech-showcase-2023 monthly 0.8 https://bioxodes.com/newsroom/events/biotech-showcase-2023 monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-presents-latest-developments-at-key-international-conferences monthly 0.8 https://bioxodes.com/newsroom/events/esoc-2023 monthly 0.8 https://bioxodes.com/newsroom/events/isth-2023-congress monthly 0.8 https://bioxodes.com/newsroom/events/bioquity-europe-2023 monthly 0.8 https://bioxodes.com/newsroom/events/esota-2023 monthly 0.8 https://bioxodes.com/newsroom/events/23rd-annual-biotech-in-europe-forum-sachs-associates monthly 0.8 https://bioxodes.com/newsroom/events/healthtech-innovation-days-5 monthly 0.8 https://bioxodes.com/newsroom/press-releases/head-of-belgian-biotech-firm-wins-business-worldwide-magazine-ceo-award monthly 0.8 https://bioxodes.com/newsroom/events/bioeurope-fall-2023 monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-closes-12-million-in-series-a-funding-round monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-to-present-first-in-class-drug-candidate-biox-101-for-hemorrhagic-stroke-to-investors-and-pharmaceutical-community-in-range-of-conferences monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-receives-european-patent-office-intention-to-grant-patent-offering-lead-asset-broad-protection-in-thromboinflammation monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-meets-first-phase-2a-patient-enrollment-milestone-with-biox-101-in-intracerebral-hemorrhagic-stroke monthly 0.8 https://bioxodes.com/newsroom/publications/evaluation-of-hemorrhage-and-edema-expansion-including-effect-on-neutrophil-mediated-neuroinflammation-in-intracerebral-hemorrhage-using-ir-cpi-a-thromboinflammation-inhibitor monthly 0.8 https://bioxodes.com/newsroom/publications/ir-cpi-reduces-brain-infiltration-of-neutrophils-releasing-extracellular-traps-and-attenuates-neuronal-degeneration-after-intracerebral-haemorrhage monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-reports-positive-dmc-meeting-for-biox-101-phase-2a-trial-in-intracerebral-hemorrhagic-stroke monthly 0.8 https://bioxodes.com/newsroom/events/brain-innovation-days monthly 0.8 https://bioxodes.com/newsroom/media-articles/six-biomimicry-biotech-companies-harnessing-natures-wisdom-to-develop-breakthrough-drug-candidates monthly 0.8 https://bioxodes.com/newsroom/publications/a-tick-molecule-to-rescue-lives-after-intracerebral-hemorrhage monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-meets-enrollment-milestone-in-phase-2a-intracerebral-hemorrhagic-stroke-trial monthly 0.8 https://bioxodes.com/newsroom/events/international-stroke-conference-2025 monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-secures-new-funds-to-reach-early-2025-milestones-and-pursue-series-b-financing monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-obtains-orphan-drug-designation-for-hemorrhagic-stroke-therapeutic-candidate-in-us-and-europe monthly 0.8 https://bioxodes.com/newsroom/events/bioeurope-spring-2025 monthly 0.8 https://bioxodes.com/newsroom/events/lsx-world-congress-europe monthly 0.8 https://bioxodes.com/newsroom/events/bioequity-europe monthly 0.8 https://bioxodes.com/newsroom/events/european-stroke-organisation-conference-2025 monthly 0.8 https://bioxodes.com/newsroom/media-articles/understanding-neuroinflammation-is-key-to-new-treatments-for-stroke monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-announces-positive-phase-2a-interim-data-for-biox-101-in-intracerebral-hemorrhagic-stroke-patients monthly 0.8 https://bioxodes.com/newsroom/media-articles/can-bioxodes-end-the-dearth-of-haemorrhagic-stroke-drugs monthly 0.8 https://bioxodes.com/newsroom/media-articles/with-new-data-in-stroke-bioxodes-looks-to-a-series-b monthly 0.8 https://bioxodes.com/newsroom/media-articles/bioxodes-halts-phase-2-stroke-trial-after-successful-interim-review-plots-registrational-study monthly 0.8 https://bioxodes.com/newsroom/media-articles/la-societe-wallonne-bioxodes-pourrait-devenir-la-premiere-a-commercialiser-un-traitement-contre-l-avc monthly 0.8 https://bioxodes.com/newsroom/media-articles/reportage-rtbf-on-bioxodes-national-tv monthly 0.8 https://bioxodes.com/newsroom/events/bio-international-convention monthly 0.8 https://bioxodes.com/newsroom/media-articles/celebrating-clinical-trials-day-part-2-trial-optimization-in-action monthly 0.8 https://bioxodes.com/newsroom/media-articles/how-bioxodes-is-rewriting-the-rules-of-haemorrhagic-stroke-treatment monthly 0.8 https://bioxodes.com/newsroom/media-articles/bioxodes-plans-to-raise-eur-70m-to-bring-to-market-its-hemorrhagic-stroke-drug-candidate-ceo monthly 0.8 https://bioxodes.com/newsroom/media-articles/accurate-diagnosis-and-enrollment-criteria-improve-intracerebral-hemorrhage-research monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-positive-phase-2a-stroke-data-show-breakthrough-potential-of-innovative-therapeutic-candidate-biox-101 monthly 0.8 https://bioxodes.com/newsroom/media-articles/biobiz-buzz-podcast-how-bioxodes-is-using-tick-saliva-to-create-an-ich-stroke-treatment-breakthrough monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-appoints-industry-veteran-philippe-monteyne-as-chairman-as-it-accelerates-late-stage-development-of-breakthrough-stroke-candidate monthly 0.8 https://bioxodes.com/newsroom/media-articles/la-biotech-bioxodes-nomme-un-ancien-haut-responsable-de-gsk-a-sa-presidence monthly 0.8 https://bioxodes.com/newsroom/media-articles/stroke-research-progresses-towards-new-frontier monthly 0.8 https://bioxodes.com/newsroom/media-articles/bioxodes-haemorrhagic-stroke-hopeful-to-progress-after-phase-ii-success monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-presents-biox-101-clinical-data-showing-breakthrough-potential-for-stroke-in-webcast-with-prof-dr-robin-lemmens monthly 0.8 https://bioxodes.com/newsroom/press-releases/bioxodes-raises-55-million-series-a-extension-to-continue-preparations-for-pivotal-trial-of-breakthrough-stroke-candidate monthly 0.8 https://bioxodes.com/newsroom/events/biotech-showcase-jp-morgan-week monthly 0.8 https://bioxodes.com/newsroom/media-articles/belgen-jagen-op-kerkhof-voor-investeerders-op-behandeling-tegen-hersenbloeding monthly 0.8 https://bioxodes.com/newsroom/media-articles/bioxodes-leve-5-5-millions-pour-financer-la-suite-de-ses-recherches-autour-de-l-avc monthly 0.8 https://bioxodes.com/newsroom/events/european-neuroscience-innovation-forum-organized-by-sachs-associates monthly 0.8 https://bioxodes.com/newsroom/events/lsx-world-congress-europe monthly 0.8 https://bioxodes.com/newsroom/events/bioeurope-spring-2026 monthly 0.8 https://bioxodes.com/newsroom/media-articles/mapping-rare-disease-in-2026-report-by-stifel monthly 0.8